Reinhart Partners LLC. Invests $46.15 Million in ICU Medical, Inc. $ICUI

Reinhart Partners LLC. bought a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 314,768 shares of the medical instruments supplier’s stock, valued at approximately $46,148,000. Reinhart Partners LLC. owned approximately 1.26% of ICU Medical at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. AQR Capital Management LLC increased its stake in ICU Medical by 2.5% in the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock valued at $1,297,000 after purchasing an additional 229 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of ICU Medical by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after buying an additional 560 shares during the last quarter. United Services Automobile Association purchased a new stake in shares of ICU Medical during the 1st quarter worth approximately $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of ICU Medical by 32.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock valued at $9,472,000 after buying an additional 16,680 shares in the last quarter. Finally, Intech Investment Management LLC boosted its holdings in shares of ICU Medical by 38.6% in the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock valued at $1,658,000 after buying an additional 3,326 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insiders Place Their Bets

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the transaction, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. This trade represents a 11.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the transaction, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. The trade was a 23.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.10% of the company’s stock.

Key Headlines Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

Analyst Upgrades and Downgrades

ICUI has been the topic of a number of research analyst reports. Zacks Research cut ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. BTIG Research upped their target price on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday. Piper Sandler lifted their price target on ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a research report on Friday. Needham & Company LLC boosted their price objective on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research note on Friday. Finally, Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $192.80.

ICU Medical Stock Up 10.9%

ICU Medical stock opened at $184.56 on Friday. The stock has a 50 day moving average of $151.64 and a two-hundred day moving average of $141.02. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $192.85. The stock has a market capitalization of $4.61 billion, a price-to-earnings ratio of 156.41, a PEG ratio of 2.32 and a beta of 0.74. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a return on equity of 7.94% and a net margin of 1.39%.The business had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. During the same quarter in the previous year, the company posted $2.10 earnings per share. The company’s revenue for the quarter was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, research analysts expect that ICU Medical, Inc. will post 6.51 earnings per share for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.